Weiss Ratings Reiterates Sell (E+) Rating for InterCure (NASDAQ:INCR)

Key Points

• Weiss Ratings has reaffirmed a "sell (E+)" rating for InterCure (NASDAQ: INCR), indicating continued caution regarding the stock's potential.
• InterCure's stock opened at $1.61 on Wednesday and has fluctuated between a 1-year low of $1.17 and a high of $1.87.
• The company specializes in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis products for medical use, primarily in Israel and internationally.

InterCure (NASDAQ:INCR - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

InterCure Price Performance

Shares of INCR stock opened at $1.61 on Wednesday. InterCure has a 1-year low of $1.17 and a 1-year high of $1.87. The firm has a fifty day moving average of $1.57 and a two-hundred day moving average of $1.51.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.